Flot.bio x Philip Hemme cover image

Otello Stampacchia, Omega Funds 🇮🇹 | M&A, Boston & Pasta | E18

Flot.bio x Philip Hemme

00:00

Intro

This chapter explores the competitive dynamics of the biopharma industry, emphasizing the challenges posed by a lack of clinical-stage assets. It examines the trend of smaller transactions amid regulatory changes and how the shift towards private markets influences access to late-stage opportunities.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app